Genomics Reporting Implementation Guide
3.0.0-ballot - Ballot International flag

This page is part of the Genetic Reporting Implementation Guide (v3.0.0-ballot: STU 3 Ballot 1) based on FHIR (HL7® FHIR® Standard) R4. The current version which supersedes this version is 2.0.0. For a full list of available versions, see the Directory of published versions

Example Observation: EGFR-L858R-therapuDrug2

Generated Narrative: Observation

Resource Observation "EGFR-L858R-therapuDrug2"

Profile: Therapeutic Implication

status: final

category: Laboratory (Observation Category Codes#laboratory), Genetics (diagnosticServiceSectionId#GE)

code: Therapeutic Implication (To Be Determined Codes#therapeutic-implication)

subject: Patient/somaticPatient " HAMSBURG"

effective: 2023-02-01

performer: Practitioner/pathologistPractitioner " DOLIN"

derivedFrom: Observation/EGFR-L858R-var

component

code: Therapeutic Implication (To Be Determined Codes#therapeutic-implication)

value: Responsive (LOINC#LA6677-4)

component

Related Artifact for Observation component:

code: Level of evidence (LOINC#93044-6)

value: Tier I - Level A ()

component

code: Associated phenotype (LOINC#81259-4)

value: Non-small cell lung cancer (SNOMED CT#254637007 "Non-small cell lung cancer (disorder)")

component

Related Artifact for Observation component:

code: Medication assessed (LOINC#51963-7)

value: Erlotinib ()

component

Related Artifact for Observation component:

code: Conclusion Text (To Be Determined Codes#conclusion-string)

value: Non-small cell lung cancer with EGFR L858R mutation is sensitive to erlotinib